Is Regeneron a Buy After the FDA Approved its Gene Therapy to Restore Hearing?

Regeneron reported first-quarter revenue of $3.6 billion, up 19% year over year and ahead of the $3.48 billion consensus, while adjusted EPS rose 15% to $9.47. Growth in Libtayo (+54% to $438 million) and Dupixent (+36% to $1.6 billion) offset a 10% decline in Eylea sales to $941 million, and management authorized a new $3 billion buyback after spending $803 million in Q1. The FDA also granted accelerated approval for Otarmeni, supporting the company’s pipeline narrative despite near-term pressure from Eylea competition.

Analysis

The market is treating this as an Eylea deceleration story, but the deeper setup is a portfolio-transition trade: REGN is shifting from one mature franchise to a broader multiple-driver earnings base. The key second-order effect is that share loss in an older cash cow is being partially recycled into higher-quality mix from Dupixent/Libtayo plus pipeline optionality, which reduces the probability of a true earnings cliff over the next 12-18 months. That matters because biotech de-ratings usually happen when the core asset is declining and the rest of the portfolio is still pre-monetization; here, the bridge is already visible.

The real near-term catalyst is not the headline revenue print but capital allocation and regulatory positioning. The new buyback authorization signals management believes the stock is discounting a higher terminal erosion rate than their internal model implies, and that tends to support the name on down days. Meanwhile, the Otarmeni/U.S. pricing arrangement may look like a giveaway, but it likely buys a longer window of pricing flexibility for the remainder of the portfolio — a valuable insurance policy as policy risk becomes a larger part of pharma valuation math.

Consensus is probably underestimating how much of REGN’s current valuation already prices in Eylea share loss while giving little credit for pipeline execution. The risk is that Vabysmo pressure accelerates faster than Eylea HD can offset, creating a 2-3 quarter EPS air pocket; that would be enough to cap the rerating even if the long-term story remains intact. On balance, the move looks overdone for investors with a 6-12 month horizon, but it is not a clean momentum long because the stock still needs proof that the non-Eylea portfolio can sustain growth into 2026.

For competitors, Sanofi benefits indirectly if Dupixent durability is reaffirmed, while Roche is the most obvious beneficiary of any further Eylea share leakage. The broader biotech basket may also get a small sentiment lift if REGN’s pipeline breadth is rewarded, but single-asset ophthalmology names should trade weaker on the message that innovation can be displaced quickly once a superior competitor gains reimbursement traction.

Key Decisions for Investors

• Go long REGN on weakness for a 6-12 month horizon; target a re-rate back toward a low-20s forward multiple if pipeline and buybacks continue to offset Eylea pressure. Stop-loss on evidence of two consecutive quarters of faster-than-expected Eylea decline.
• Use a REGN/RHHBY pair trade: long REGN, short Roche ADRs or relevant Roche exposure over 3-6 months. The market is already pricing in ophthalmology disruption, but REGN has more self-help via buybacks and diversification.
• Buy REGN Jan-2027 calls or call spreads instead of stock if you want pipeline convexity with defined downside. The setup is attractive because late-stage readouts and regulatory optionality can reprice the name without needing a full earnings recovery first.
• Avoid shorting REGN outright here; the risk/reward is poor unless you have high conviction that Eylea HD adoption stalls and Libtayo/Dupixent growth decelerates simultaneously. The buyback provides a natural bid on drawdowns.
• For a relative-value hedge, pair long REGN against a basket of single-product or single-franchise biotech names. REGN’s diversified growth profile makes it a better defensive biotech holding if broader risk appetite weakens.